ArticleCureus2025
Transurethral Resection of Bladder Tumors Using Holmium Laser: An Observational Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Bladder cancer ranks as the ninth most frequently diagnosed malignancy globally. Although conventional treatment, i.e., transurethral resection of the bladder tumor (TURBT), remains the gold-standard procedure for early-stage bladder cancer, it carries well-documented risks such as bleeding, perforation, and prolonged catheter dependence. In contrast, holmium laser resection promises several theoretical benefits, namely, lower thermal damage to surrounding tissues, reduced incidence of the obturator nerve reflex, and superior control of intraoperative bleeding. Methodology This cross-sectional observational study was conducted at the Department of Urology, Mahatma Gandhi Medical College and Research Institute, Puducherry, between December 2021 and June 2023. In total, 24 patients older than 18 years and diagnosed with superficial bladder carcinoma (Tis, Ta, T1, N0, M0) underwent holmium laser-assisted transurethral resection. Operative time, complication rates, duration of catheterization, length of hospital stay, and histological results were systematically recorded and analyzed. Results The study population comprised 62.5% males and 37.5% females. Hematuria was the most common presenting symptom (58.3%). The majority of tumors were located in the right lateral wall (37.5%) and posterior wall (25.0%). Single lesions predominated (70.8%). The median operative time was 32.50 minutes, with a median catheterization time of two days and a hospital stay of 1.50 days. Complications included bladder perforation (8.3%) and obturator reflex (12.5%). Tumor staging showed 62.5% T1 and 37.5% Ta stages, with 58.3% classified as low-grade tumors. Conclusions Holmium laser-assisted TURBT demonstrated acceptable operative outcomes with relatively low complication rates, shorter hospital stays, and effective tumor resection. The technique appears to be a viable alternative to conventional TURBT for superficial bladder carcinoma management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.